Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in Ohio: - Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Miami Valley Hospital South — Centerville, Ohio
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in Ohio: - UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in Ohio: - Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Oncology Hematology Care Inc-Kenwood — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in Ohio: - Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- TriHealth Cancer Institute-Good Samaritan Hospital — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- The Jewish Hospital — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in Ohio: - The Christ Hospital Cancer Center — Cincinnati, Ohio
- Oncology Hematology Care — Cincinnati, Ohio
- University of Cincinnati — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Cleveland Clinic Main Campus — Cleveland, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
- Fairview Hospital — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Cleveland Clinic - Hillcrest Hospital — Mayfield Heights, Ohio
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in Ohio: - University of Cincinnati Cancer Center — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
- Louis Stokes Cleveland VA Med Ctr — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in Ohio: - University Of Cincinnati Medical Center /ID# 246415 — Cincinnati, Ohio
- Cleveland Clinic Main Campus /ID# 246183 — Cleveland, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in Ohio: - Oncology Hematology Care, Inc. - Cincinnati - Galbraith Rd — Cincinnati, Ohio
- Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center) — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Midwest Oncology Associates - Kansas City — Kansas, Ohio
- Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center — Mayfield Heights, Ohio
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in Ohio: - Research Site — Cincinnati, Ohio
- Research Site — Cleveland, Ohio
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- Seidman Cancer Center-University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Ohio State Medical Center, James Cancer Center — Columbus, Ohio
- Ohio Health Research Institute — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in Ohio: - GSK Investigational Site — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …
Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in Ohio: - GC2202 Study Site 105 — Canton, Ohio
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio
- Kettering Health — Kettering, Ohio
- West Chester Hospital — West Chester, Ohio
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period o…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06232044
Sites in Ohio: - OhioHealth O'Bleness Hospital — Athens, Ohio
- Columbus Oncology and Hematology Associates Inc — Columbus, Ohio
- Riverside Methodist Hospital — Columbus, Ohio
- Grant Medical Center — Columbus, Ohio
- Doctors Hospital — Columbus, Ohio
Phase 2 Recruiting Industry
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants w…
Sponsor: Sanofi
NCT ID: NCT06356571
Sites in Ohio: - Gabrail Cancer Center- Site Number : 8400010 — Canton, Ohio
- University of Cincinnati Medical Center- Site Number : 8400043 — Cincinnati, Ohio
- Oncology Hematology Care - Kenwood- Site Number : 8400014 — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called r…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07266441
Sites in Ohio: - Cleveland Clinic Foundtation — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT05972135
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14)…
Sponsor: BeOne Medicines
NCT ID: NCT04973605
Sites in Ohio: - The James Cancer Hospital and Solove Research Institute At Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively trea…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03761108
Sites in Ohio: - Ohio State University James Cancer Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumu…
Sponsor: Indapta Therapeutics, INC.
NCT ID: NCT06119685
Sites in Ohio: - University Hospitals Cleveland — Cleveland, Ohio